EDWARDS LIFESCIENC revenue breakdown overview

EDWARDS LIFESCIENC revenue for the last year amounted to 5.06 B CHF, the most of which — 3.43 B CHF — came from its highest performing source at the moment, Transcatheter Mitral and Tricuspid Therapies, the year earlier bringing 3.36 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought EDWARDS LIFESCIENC 2.95 B CHF, and the year before that — 2.90 B CHF.